Year: 2018
Type: article
Abstract: Gene expression assays are commonly used to aid clinical decision-making in early stage estrogen receptor (ER)-positive, Her2-negative breast cancer because they provide complementary prognostic information to clinicopathologic features. Currently available assays include the 21-gene Oncotype DX® Recurrence Score (Genomic Health, Inc., Redwood City, CA), 1 the 70-gene MammaPrint® assay (Agendia Inc., USA), 2 and others. 3 The 21-gene and 70-gene assays also provide predictive information for chemotherapy benefit 4 , 5 or lack thereof because of a very low recurrence risk with endocrine therapy alone, 2 , 6 , 7 providing a foundation for their recommendation in practice guidelines. 3 , 8 Evidence supporting the clinical utility of the 70-gene assay was provided by the MINDACT trial, which showed that tumors associated with high clinical risk and low genomic risk by the 70-gene assay had a distant metastasis-free survival (DMFS) of 95% with endocrine therapy alone, which met the prespecified primary trial end point. 2 Information provided by these assays result in a treatment change for up to 25%, usually in the direction of sparing chemotherapy. 9
Source: npj Breast Cancer
Author: Joseph A. Sparano
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W2803436593